862608-10-4

Upstream product

• 122058-30-4 4-methylcinnamyl alcohol 
• 20511-20-0 ethyl p-methylcinnamate 
• 1147335-26-9 C₁₀H₉N₃O₄ 
• 1147334-99-3 C₁₀H₈N₂O₄ 
• 1866-39-3 4-methylcinnamic acid 
• 1147335-53-2 3-cyano-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide 
• 23855-31-4 4-(4-methoxyphenyl)-3-methyl-1,2,5-oxadiazole 2-oxide 
• 862801-51-2 ethyl (4-(3-hydroxymethyl)furoxan-4-yl)phenyl carbonate 
• 497845-94-0 3-(bromomethyl)-4-(4-methoxyphenyl)-1,2,5-oxadiazole 2-oxide 
• 862801-50-1 3-(hydroxymethyl)-4-(4-methoxyphenyl)-1,2,5-oxadiazole-2-oxide 
• 862608-06-8 (4-(4-hydroxyphenyl)furoxan-3-yl)methanol 

Downstream Products

• 862876-46-8 4-{4-[3-(1H-imidazol-4-yl)-propoxy]-phenyl}-2-oxy-furazan-3-carboxylic acid amide 
• 1147335-56-5 3-cyano-4-(4-(prop-2-ynyloxy)phenyl)-1,2,5-oxadiazole 2-oxide 
• 862608-08-0 4-(4-hydroxyphenyl)furoxan-3-carboxamide 

Relevant academic research and scientific papers

A class of 1, 2, 5 - oxadiazole - 2 oxide analogs, its preparation and use

The invention provides 1,2,5-oxadiazole-2 oxide analogue with a structure shown as general formula I, and a preparation method and an application thereof. The 1,2,5-oxadiazole-2 oxide analogue has the activity for resisting schistosome thioredoxin glutathione reductase, kills schistosome by blocking a normal redox equilibrium physiological metabolism process of schistosome cells, can be used as a drug lead for development of drugs for treating schistosomiasis, and provides novel means for preventing and treating schistosomiasis. The general formula I is shown in the description.

OXADIAZOLE-2-OXIDES AS ANTISCHISTOSOMAL AGENTS

The invention provides 1,2,5-oxadiazole-containing compounds of Formula (I), wherein R1, A, and R2 are as defined herein, that are useful in treating schistosomiasis. The invention also provides a composition comprising a pharmaceuti

Synthesis of oxadiazole-2-oxide analogues as potential antischistosomal agents

The synthesis of several 1,2,5-oxadiazole-2-oxide (Furoxan) analogues is described herein. These compounds were prepared in an effort to probe the SAR around the phenyl substituent and oxadiazole core for our studies toward thioredoxin-glutathione reductase (TGR) inhibition and antischistosomal activity.

Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis

Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we recently identified as inhibitors of thioredoxin glutathione reductase (TGR), a selenocysteine-containing flavoenzyme required by the parasite to maintain proper cellular redox balance. Through systematic evaluation of the core molecular structure of this chemotype, we define the essential pharmacophore, establish a link between the nitric oxide donation and TGR inhibition, determine the selectivity for this chemotype versus related reductase enzymes, and present evidence that these agents can be modified to possess appropriate drug metabolism and pharmacokinetic properties. The mechanistic link between exogenous NO donation and parasite injury is expanded and better defined. The results of these studies verify the utility of oxadiazole-2-oxides as novel inhibitors of TGR and as efficacious antischistosomal agents. 2009 American Chemical Society.

Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives

Synthesis and pharmacological characterisation of a series of compounds in which the oxime substructure present in imoproxifan was constrained in the pentatomic NO-donor furoxan ring, as well as their structurally related furazan analogues devoid of NO-do